Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Agios Pharmaceuticals’ dense clinical disclosures can feel like hunting for a single mutation in a genome. R&D expenses tied to pyruvate-kinase activators, FDA feedback on sickle-cell trials, and collaboration milestone payments sprawl across hundreds of pages. If you have ever asked, “How do I read the Agios Pharmaceuticals annual report 10-K simplified?” or searched for “Agios Pharmaceuticals insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI-powered analysis turns that challenge into clarity. Our system ingests every 10-K, 10-Q, 8-K and S-1 the moment it hits EDGAR, then delivers plain-English summaries that highlight trial progress, cash runway and key risks—Agios Pharmaceuticals SEC filings explained simply. You can monitor Agios Pharmaceuticals Form 4 insider transactions real-time, receive alerts on Agios Pharmaceuticals quarterly earnings report 10-Q filing numbers, and access AI commentary that points to pivotal PK-activation data. Whether you need an Agios Pharmaceuticals earnings report filing analysis or a quick read on an Agios Pharmaceuticals 8-K material events explained, the insights are waiting.
Investors use this page to:
- Track Agios Pharmaceuticals executive stock transactions Form 4 before catalytic trial read-outs
- Compare period-over-period R&D spend without sifting through footnotes
- Review the Agios Pharmaceuticals proxy statement executive compensation for alignment with shareholder interests
- Gauge cash runway against pipeline timelines in seconds—understanding Agios Pharmaceuticals SEC documents with AI
Agios Pharmaceuticals (AGIO) Chief Commercial Officer Tsveta Milanova reported significant insider transactions on June 24, 2025. The transactions involved performance share units (PSUs) and common stock:
- 6,000 PSUs converted to common stock upon achieving a specified research milestone, representing 50% of the total PSU grant from March 1, 2023
- 2,770 shares were subsequently sold at $33.54 per share to cover tax withholding obligations
- Following these transactions, Milanova holds 26,122 shares directly
The share sale was executed under a pre-established 10b5-1 trading plan. The remaining 50% of PSUs will vest upon achievement of a specified regulatory milestone. The transactions reflect standard executive compensation practices and planned tax-related sales rather than discretionary trading decisions.
Agios Pharmaceuticals (NASDAQ: AGIO) filed a Form 4 disclosing CEO Brian Goff’s June 24 2025 equity transactions.
- PSU vesting: 25,527 and 12,750 shares (total 38,277) converted to common stock at $0 cost.
- Automatic sales for tax-withholding: 12,471 and 6,229 shares sold at $33.54, generating roughly $0.63 million.
- Net change: Beneficial ownership rose by 19,577 shares to 111,922, a ~21 % increase versus the pre-vesting position.
- Sales executed under pre-arranged Rule 10b5-1 instructions; no discretionary selling.
The filing is routine and contains no operational, financial or strategic updates.
Agios Pharmaceuticals, Inc. – Form 144 filing
An unnamed insider intends to sell 1,761 common shares of Agios Pharmaceuticals, Inc. (AGIO) through Morgan Stanley Smith Barney on 24 June 2025. The shares, worth about $60,596, were obtained the same day via the vesting of restricted stock units. With 57.9 million shares outstanding, the proposed sale equates to roughly 0.003 % of total shares, indicating an immaterial ownership change. No other insider sales were reported in the past three months, and the filer certified that no undisclosed adverse information is known.
Agios Pharmaceuticals, Inc. (AGIO) has filed a Form 144 with the U.S. Securities and Exchange Commission disclosing a proposed insider sale under Rule 144.
- Shares to be sold: 1,761 shares of common stock
- Aggregate market value: $60,596
- Approximate sale date: 06/24/2025
- Broker: Morgan Stanley Smith Barney LLC, New York, NY
- Shares outstanding: 57,915,199
- Source of shares: Vesting of restricted stock on 06/24/2025
- Exchange: Nasdaq
The proposed sale represents roughly 0.003% of the company’s outstanding shares, indicating a de-minimis transaction that is unlikely to have a material effect on the company’s capital structure or market liquidity. No prior sales were reported in the past three months, and the filer attests to possessing no undisclosed material adverse information.
Agios Pharmaceuticals, Inc. (AGIO) has filed a Form 144 indicating the intended sale of 1,761 common shares through Morgan Stanley Smith Barney LLC. The shares were acquired via the vesting of restricted stock units on 24 June 2025 and are targeted for sale on the same date. At an aggregate market value of $60,596, the proposed disposition represents roughly 0.003 % of the company’s 57.9 million shares outstanding. No other sales have been reported by the filer during the past three months.
The notice affirms that the seller possesses no undisclosed material adverse information about AGIO at the time of filing, as required under Rule 144. Because the volume and value are immaterial relative to the company’s market capitalization and daily trading volume, the filing is largely routine and unlikely to affect the share price.
Form 4 Filing Overview – Agios Pharmaceuticals (AGIO), 23 Jun 2025
Director Rahul D. Ballal reported several equity-based transactions executed on 18 and 20 June 2025. The filing shows no open-market sales; all movements relate to equity awards and the conversion of previously granted restricted stock units (RSUs).
- Equity Award Grants (18 Jun 2025)
- 2,816 RSUs – vest 100% on 18 Jun 2026.
- 15,768 stock options – exercise price $35.50, vest 100% on 18 Jun 2026, expire 18 Jun 2035.
- RSU Conversion (20 Jun 2025)
- 2,120 shares of common stock acquired at $0 cost via automatic conversion of RSUs granted 20 Jun 2024.
- Post-transaction holdings: 10,112 common shares held directly; zero derivative RSUs remain from the 2024 grant; 15,768 unexercised options and 2,816 unvested RSUs newly awarded.
The transactions increase Ballal’s direct ownership by 2,120 shares and reinforce his long-term incentive alignment through a fresh option package. Because the activity consists solely of routine compensation grants and vesting with no disposals, the immediate market impact is normally limited; however, the additional share ownership may be viewed positively by investors monitoring insider sentiment.
Agios Pharmaceuticals, Inc. (AGIO) – Form 4 filing reports routine equity transactions by director Jeffrey D. Capello.
New equity awards (granted 18-Jun-2025):
- 2,861 Restricted Stock Units (RSUs); vest 100% on 18-Jun-2026.
- 15,768 Non-qualified Stock Options with a $35.50 exercise price; options vest 100% on 18-Jun-2026 and expire 18-Jun-2035.
RSU conversion (20-Jun-2025):
- Capello received 2,120 common shares (Transaction Code “M”) at $0 cost upon full vesting of a June 2024 RSU grant.
Post-transaction ownership (direct):
- 6,073 common shares (includes newly delivered 2,120 shares).
- 2,861 unvested RSUs.
- 15,768 options at $35.50.
The filing reflects standard director compensation and scheduled vesting; no open-market purchases or sales occurred. No change to board composition or strategy was disclosed.
Form 4 filing overview: On 06/23/2025, Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) reported changes in the beneficial ownership of director Kaye I. Foster-Cheek.
- New equity grants (06/18/2025): • 2,816 restricted stock units (RSUs) that vest in full on 06/18/2026. • 15,768 stock options with a $35.50 exercise price, also vesting 100% on 06/18/2026 and expiring 06/18/2035.
- RSU conversion (06/20/2025): 2,120 previously granted RSUs vested and were converted into an equal number of common shares at $0 cost (code M). These shares were added to her direct holdings.
- Post-transaction ownership: • Direct: 7,468 common shares. • Indirect: 2,200 shares held by the Foster Family Revocable Trust.
No shares were sold and no cash purchases were reported. All transactions were equity-based awards or conversions, indicating routine director compensation and continued share ownership.
FAQ
What is the current stock price of Agios Pharmaceuticals (AGIO)?
What is the market cap of Agios Pharmaceuticals (AGIO)?
